

William Perry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11611727/publications.pdf>

Version: 2024-02-01

99
papers

5,844
citations

81434

41
h-index

90395

73
g-index

102
all docs

102
docs citations

102
times ranked

5872
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Prior Chronic Methamphetamine Treatment and gp120 Expression Reduce PPI in Aged Male but not Female Mice. <i>Neuroscience Letters</i> , 2022, , 136639.	1.0	2
2	The Effects of Cannabis Use on Cognitive Function in Healthy Aging: A Systematic Scoping Review. <i>Archives of Clinical Neuropsychology</i> , 2021, 36, 673-685.	0.3	10
3	Both HIV and Tat expression decrease prepulse inhibition with further impairment by methamphetamine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110089.	2.5	10
4	The relationship between cannabis use and cognition in people with bipolar disorder: A systematic scoping review. <i>Psychiatry Research</i> , 2021, 297, 113695.	1.7	5
5	Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. <i>Behavioural Brain Research</i> , 2021, 405, 113167.	1.2	1
6	The Relationships between HIV-1 Infection, History of Methamphetamine Use Disorder, and Soluble Biomarkers in Blood and Cerebrospinal Fluid. <i>Viruses</i> , 2021, 13, 1287.	1.5	5
7	Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporter-deficient mice using the 5-choice CPT. <i>Bipolar Disorders</i> , 2020, 22, 46-58.	1.1	21
8	Sustained attention and vigilance deficits associated with HIV and a history of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108245.	1.6	9
9	Integrative Care Models in Neuropsychology: A National Academy of Neuropsychology Education Paper. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 141-151.	0.3	5
10	Dopamine transporter knockdown mice in the behavioral pattern monitor: A robust, reproducible model for mania-relevant behaviors. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 178, 42-50.	1.3	15
11	Amphetamine Modestly Improves Conners™ Continuous Performance Test Performance in Healthy Adults. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 283-293.	1.2	26
12	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. <i>Innovation in Aging</i> , 2018, 2, igy025.	0.0	15
13	Amphetamine improves mouse and human attention in the 5-choice continuous performance test. <i>Neuropharmacology</i> , 2018, 138, 87-96.	2.0	37
14	Everyday functional ability in HIV and methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2017, 175, 60-66.	1.6	10
15	Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species. <i>Neuropharmacology</i> , 2017, 125, 254-262.	2.0	17
16	The COMT Val158Met Polymorphism and Exploratory Behavior in Bipolar Mania. <i>Molecular Neuropsychiatry</i> , 2017, 3, 151-156.	3.0	6
17	The Association between Psychiatric Comorbidities and Outcomes for Inpatients with Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2017, 34, 1005-1016.	1.7	22
18	Diagnosis and characterization of mania: Quantifying increased energy and activity in the human behavioral pattern monitor. <i>Psychiatry Research</i> , 2016, 240, 278-283.	1.7	13

#	ARTICLE	IF	CITATIONS
19	Amphetamine increases activity but not exploration in humans and mice. <i>Psychopharmacology</i> , 2016, 233, 225-233.	1.5	33
20	Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 251-258.	1.3	33
21	Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. <i>European Neuropsychopharmacology</i> , 2015, 25, 141-150.	0.3	37
22	Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 58, 4-18.	2.9	25
23	The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. <i>European Journal of Pharmacology</i> , 2015, 753, 114-126.	1.7	81
24	Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment. <i>Journal of NeuroVirology</i> , 2014, 20, 561-570.	1.0	28
25	Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. <i>Behavioural Pharmacology</i> , 2014, 25, 12-22.	0.8	31
26	Reduced Dopamine Transporter Functioning Induces High-Reward Risk-Preference Consistent with Bipolar Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 3112-3122.	2.8	78
27	Elevated intraindividual variability in methamphetamine dependence is associated with poorer everyday functioning. <i>Psychiatry Research</i> , 2014, 220, 527-534.	1.7	18
28	Inhibitory deficits in euthymic bipolar disorder patients assessed in the human behavioral pattern monitor. <i>Journal of Affective Disorders</i> , 2013, 150, 948-954.	2.0	31
29	Everyday functional ability across different phases of bipolar disorder. <i>Psychiatry Research</i> , 2013, 210, 850-856.	1.7	35
30	Prepulse Inhibition in HIV-Associated Neurocognitive Disorders. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 709-717.	1.2	34
31	Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. <i>Behavioural Brain Research</i> , 2013, 236, 210-220.	1.2	27
32	Intra-Individual Variability Across Neurocognitive Domains in Chronic Hepatitis C Infection: Elevated Dispersion is Associated With Serostatus and Unemployment Risk. <i>Clinical Neuropsychologist</i> , 2012, 26, 654-674.	1.5	18
33	Assessment and Usefulness of Clinical Scales for Semiquantification of Overt Hepatic Encephalopathy. <i>Clinics in Liver Disease</i> , 2012, 16, 27-42.	1.0	7
34	Effect of methamphetamine dependence on heart rate variability. <i>Addiction Biology</i> , 2012, 17, 648-658.	1.4	58
35	Repeated Assessment of Exploration and Novelty Seeking in the Human Behavioral Pattern Monitor in Bipolar Disorder Patients and Healthy Individuals. <i>PLoS ONE</i> , 2011, 6, e24185.	1.1	44
36	Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. <i>Psychopharmacology</i> , 2011, 215, 697-707.	1.5	31

#	ARTICLE	IF	CITATIONS
37	Revising the Rorschach Ego Impairment Index to Accommodate Recent Recommendations About Improving Rorschach Validity. <i>International Journal of Testing</i> , 2011, 11, 349-364.	0.2	22
38	GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. <i>Psychopharmacology</i> , 2010, 208, 443-454.	1.5	71
39	Role of Sleep Disturbance in Chronic Hepatitis C Infection. <i>Current Hepatitis Reports</i> , 2010, 9, 25-29.	0.3	29
40	Heart rate variability in bipolar mania and schizophrenia. <i>Journal of Psychiatric Research</i> , 2010, 44, 168-176.	1.5	162
41	The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 96, 7-15.	1.3	56
42	The quantitative assessment of motor activity in mania and schizophrenia. <i>Journal of Affective Disorders</i> , 2010, 120, 200-206.	2.0	84
43	Cross-species assessments of motor and exploratory behavior related to bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 1296-1306.	2.9	58
44	Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2010, 32, 637-644.	0.8	16
45	Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. <i>Psychiatry Research</i> , 2010, 178, 84-91.	1.7	69
46	Effect of methamphetamine dependence on everyday functional ability. <i>Addictive Behaviors</i> , 2010, 35, 593-598.	1.7	75
47	Beyond the Numbers: Expanding the Boundaries of Neuropsychology. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 21-29.	0.3	5
48	A Reverse-Translational Study of Dysfunctional Exploration in Psychiatric Disorders. <i>Archives of General Psychiatry</i> , 2009, 66, 1072.	13.8	174
49	Prepulse inhibition of startle in adults with ADHD. <i>Journal of Psychiatric Research</i> , 2009, 43, 484-489.	1.5	42
50	Performance of the Hepatic Encephalopathy Scoring Algorithm in a Clinical Trial of Patients With Cirrhosis and Severe Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2009, 104, 1392-1400.	0.2	74
51	Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). <i>Digestive Diseases and Sciences</i> , 2008, 53, 529-538.	1.1	66
52	Cognitive Dysfunction in Chronic Hepatitis C: A Review. <i>Digestive Diseases and Sciences</i> , 2008, 53, 307-321.	1.1	124
53	Developing New Drugs for Schizophrenia: From Animals to the Clinic. , 2008, , 199-261.		18
54	Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2008, 30, 805-815.	0.8	30

#	ARTICLE	IF	CITATIONS
55	Utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in patients with end-stage liver disease awaiting liver transplant. Archives of Clinical Neuropsychology, 2007, 22, 175-186.	0.3	62
56	A Method to Optimize the Response Range While Maintaining Rorschach Comprehensive System Validity. Journal of Personality Assessment, 2007, 89, 149-161.	1.3	53
57	The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients. Schizophrenia Research, 2007, 89, 225-231.	1.1	46
58	Sensorimotor Gating Deficits in Adults with Autism. Biological Psychiatry, 2007, 61, 482-486.	0.7	342
59	Adults with Autism Show Increased Sensitivity to Outcomes at Low Error Rates During Decision-Making. Journal of Autism and Developmental Disorders, 2007, 37, 1279-1288.	1.7	24
60	A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor. Neuroscience and Biobehavioral Reviews, 2007, 31, 882-896.	2.9	104
61	Effect of Interferon- α on cognitive functioning in patients with chronic hepatitis C. Journal of the International Neuropsychological Society, 2005, 11, 16-22.	1.2	37
62	Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. Aids, 2005, 19, S79-S84.	1.0	43
63	Biopsychosocial predictors of fatigue in chronic hepatitis C. Journal of Psychosomatic Research, 2005, 58, 173-178.	1.2	37
64	A retrospective review of the neuropsychological test performance of physicians referred for medical infractions. Archives of Clinical Neuropsychology, 2005, 20, 161-170.	0.3	26
65	Visual scanning deficits in schizophrenia and their relationship to executive functioning impairment. Schizophrenia Research, 2005, 74, 69-79.	1.1	72
66	Prepulse inhibition in patients with non-psychotic major depressive disorder. Journal of Affective Disorders, 2004, 81, 179-184.	2.0	52
67	Increased sensitivity to error during decision-making in bipolar disorder patients with acute mania. Journal of Affective Disorders, 2004, 82, 203-208.	2.0	38
68	A process approach to verbal fluency in patients with schizophrenia. Schizophrenia Research, 2004, 68, 105-106.	1.1	6
69	Pupillary dilation to simple vs. complex tasks and its relationship to thought disturbance in schizophrenia patients. International Journal of Psychophysiology, 2004, 52, 53-62.	0.5	36
70	Refinements in the Rorschach Ego Impairment Index Incorporating the Human Representational Variable. Journal of Personality Assessment, 2003, 81, 149-156.	1.3	73
71	The Use of the Ego Impairment Index Across the Schizophrenia Spectrum. Journal of Personality Assessment, 2003, 80, 50-57.	1.3	34
72	Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. Journal of the International Neuropsychological Society, 2003, 9, 847-857.	1.2	183

#	ARTICLE	IF	CITATIONS
73	Modifying the Rorschach Human Experience Variable to Create the Human Representational Variable. <i>Journal of Personality Assessment</i> , 2003, 81, 64-73.	1.3	22
74	Let's Call the Whole Thing Off: A Response to Dawes (2001).. <i>Psychological Assessment</i> , 2003, 15, 582-585.	1.2	3
75	Information Processing Deficits in Acutely Psychotic Schizophrenia Patients Medicated and Unmedicated at the Time of Admission. <i>American Journal of Psychiatry</i> , 2002, 159, 1375-1381.	4.0	70
76	Assessing disturbed thinking and cognition using the Ego Impairment Index in older schizophrenia patients: paranoid vs. nonparanoid distinction. <i>Schizophrenia Research</i> , 2002, 53, 199-207.	1.1	20
77	Neuropsychological impairment in patients with chronic hepatitis C. <i>Hepatology</i> , 2002, 35, 440-446.	3.6	253
78	Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. <i>Schizophrenia Research</i> , 2001, 49, 171-178.	1.1	257
79	Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. <i>Biological Psychiatry</i> , 2001, 50, 418-424.	0.7	249
80	Self-monitoring enhances Wisconsin Card Sorting Test performance in patients with schizophrenia: Performance is improved by simply asking patients to verbalize their sorting strategy. <i>Journal of the International Neuropsychological Society</i> , 2001, 7, 344-352.	1.2	44
81	Incremental validity of the Ego Impairment Index: A re-examination of Dawes (1999).. <i>Psychological Assessment</i> , 2001, 13, 403-407.	1.2	10
82	Schizophrenia patients demonstrate a dissociation on declarative and non-declarative memory tests. <i>Schizophrenia Research</i> , 2000, 46, 167-174.	1.1	62
83	Sensorimotor Gating and Thought Disturbance Measured in Close Temporal Proximity in Schizophrenic Patients. <i>Archives of General Psychiatry</i> , 1999, 56, 277.	13.8	236
84	The nonlinear, complex sequential organization of behavior in schizophrenic patients: neurocognitive strategies and clinical correlations. <i>Biological Psychiatry</i> , 1999, 46, 662-670.	0.7	24
85	Cognitive functions in schizotypal personality disorder. <i>Schizophrenia Research</i> , 1999, 37, 123-132.	1.1	98
86	The relationship between skin conductance hyporesponsivity and perseverations in schizophrenia patients. <i>Biological Psychiatry</i> , 1998, 44, 459-465.	0.7	21
87	A multimethod approach to assessing perseverations in schizophrenia patients. <i>Schizophrenia Research</i> , 1998, 33, 69-77.	1.1	59
88	Information processing deficits of schizophrenia patients: relationship to clinical ratings, gender and medication status. <i>Schizophrenia Research</i> , 1997, 28, 51-62.	1.1	142
89	The relationship of information-processing deficits and clinical symptoms in schizotypal personality disorder. <i>Biological Psychiatry</i> , 1996, 40, 853-858.	0.7	48
90	Latent inhibition in schizophrenia. <i>Schizophrenia Research</i> , 1996, 20, 91-103.	1.1	185

#	ARTICLE	IF	CITATIONS
91	A Neuropsychological Approach to the Rorschach in Patients with Dementia of the Alzheimer Type. <i>Assessment</i> , 1996, 3, 351-363.	1.9	35
92	The nature of learning and memory impairments in schizophrenia. <i>Journal of the International Neuropsychological Society</i> , 1995, 1, 88-99.	1.2	256
93	A Five-Year Follow-up on the Temporal Stability of the Ego Impairment Index. <i>Journal of Personality Assessment</i> , 1995, 64, 112-118.	1.3	54
94	Amphetamine on Rorschach Measures in Normal Subjects. <i>Journal of Personality Assessment</i> , 1995, 64, 456-465.	1.3	33
95	The Ego Impairment Index and Schizophrenia: A Validation Study. <i>Journal of Personality Assessment</i> , 1992, 59, 165-175.	1.3	67
96	The Ego Impairment Index as a Predictor of Outcome in Melancholic Depressed Patients Treated With Tricyclic Antidepressants. <i>Journal of Personality Assessment</i> , 1991, 56, 487-501.	1.3	104
97	Chlorpromazine and brain-stimulation reward: Potentiation of effects by naloxone. <i>Pharmacology Biochemistry and Behavior</i> , 1981, 15, 903-905.	1.3	15
98	Effects of chronic naloxone treatment on brain-stimulation reward. <i>Pharmacology Biochemistry and Behavior</i> , 1981, 14, 247-249.	1.3	36
99	Effects of d-amphetamine and naloxone on brain stimulation reward. <i>Psychopharmacology</i> , 1980, 69, 187-191.	1.5	119